Findings from a German researcher show insulin-raising drugs (GLP-1s) from Novo Nordisk (NVO...

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

Findings from a German researcher show insulin-raising drugs (GLP-1s) from Novo Nordisk (NVO -2.9%), Amlyin Pharmaceuticals (AMLN +0.5%) and Eli Lilly (LLY +0.5%) don't increase the risk of cancer, refuting research coming out of UCLA. Doctors are increasing their usage of GLP-1 medicines to treat the 366M people affected globally by diabetes.